the newer agents , cefaclor , cefuroxime axetil , and cefixime , have increased in vitro activity against beta-lactamase-secreting strains of haemophilus influenzae and branhamella catarrhalis which has made them more popular for the treatment of otitis media and respiratory tract infections in children .
C0007537
cefaclor
C0029882
otitis media